Bardia A et al. Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer. J Clin Oncol 2021;39(12):1360-70. Abstract

Hanker AB et al. Overcoming endocrine resistance in breast cancer. Cancer Cell 2020;37(4):496-513. Abstract

Hurvitz SA et al. VERITAC update: Phase II study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. San Antonio Breast Cancer Symposium 2023;Abstract 205P.

Oliveira M et al. Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. San Antonio Breast Cancer Symposium 2023;Abstract GS3-02.

Patel MR et al. Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer. ASCO 2024;Abstract 3074.

Salama AKAA et al. Targeted protein degradation: Clinical advances in the field of oncology. Int J Mol Sci 2022;23(23). Abstract